The FDA’s July 2026 peptide vote, explained

An FDA advisory committee voted on 23 and 24 July 2026 to recommend that US compounding pharmacies be allowed to use six peptides: BPC-157, KPV, TB-500, MOTS-c, epitalon and Semax. A seventh, emideltide, was narrowly rejected. The committee backed them against the advice of the FDA’s own scientists, who had recommended against all seven. The recommendation opens a rulemaking path that could put these peptides on the 503A bulks list, the ingredient list a state-licensed pharmacy may use to make a drug for an individual patient on prescription.

There has been a lot of confident commentary about this meeting, some of it wrong in both directions. Here is what happened, what it changes, and what it doesn’t, checked against the FDA’s own documents and the trade and legal press.

What the committee was asked

The Pharmacy Compounding Advisory Committee (PCAC) advises the FDA on which bulk ingredients compounding pharmacies may use. Its question was narrow: should each peptide be added to the 503A bulks list, the list of ingredients a state-licensed pharmacy can use to make a drug for an individual patient on prescription [1,2]?

Each peptide was nominated for specific conditions. The FDA’s meeting page lists them as follows [1].

The FDA had not posted official minutes on its meeting page when we checked [1], so these tallies come from reporters and lawyers who followed the meeting. They agree on six of the seven. For epitalon, STAT and a law-firm summary from McDermott report 7–4, while RAPS reports 7–5 with one abstention [4,5,6]. McDermott also records one abstention on Semax that other reports don’t mention [4]. None of this changes an outcome.

What the FDA’s scientists said

The FDA’s briefing document is blunt. For every one of the 14 substances on the agenda, the free base and acetate salt of each peptide, the agency proposed that it NOT be included on the 503A bulks list [2]. Reporting from the meeting describes FDA staff stressing a general lack of quality data on safety and effectiveness [3].

The FDA’s earlier reasoning for BPC-157, still published on its website, gives the flavour: possible immune reactions depending on the route, complexities with peptide-related impurities and characterising the active ingredient, and no or only limited safety information [7]. That is a complaint about missing evidence and uncertain material, not a finding that the peptide is dangerous.

One procedural detail has had little attention. The briefing document footnotes show that every nomination on the agenda had been withdrawn by the people who made it, and the FDA chose to bring each peptide to the committee anyway [2].

How we got here

Leaving Category 2 in April did not make these peptides legal to compound. Removal does not, by itself, place a substance on the 503A bulks list [8].

What the vote does not do

It doesn’t change the law. Advisory committees advise. A law-firm analysis published on 4 August put it plainly: these peptides “still cannot be lawfully compounded”, and the FDA can still take action against pharmacies that make them. The two ways to change that are notice-and-comment rulemaking by the FDA, or Congress amending the statute [9].

It isn’t approval. Even if the FDA adds a peptide to the bulks list, compounded drugs are not FDA-approved. The agency doesn’t check their safety, effectiveness or quality before they are marketed [10].

It isn’t new evidence. The vote changed a regulatory position. The published research on each peptide is exactly what it was the day before.

It only applies in the US. The 503A list governs American compounding pharmacies. It has no legal effect in the UK, where unlicensed medicines are regulated separately by the MHRA.

What the human evidence looks like

The FDA reviewers’ complaint was about the shape of the evidence, so it is worth being precise about it.

For TB-500, the human trials people cite were actually run on thymosin beta-4, the full-length protein that TB-500 is derived from, given as eye drops. A 2015 phase 2 trial in nine people with severe dry eye reported a 35.1% reduction in ocular discomfort and a 59.1% reduction in corneal staining against placebo at day 56 [11]. A larger phase 2 trial, with 72 people, missed both of its primary endpoints, though some secondary measures improved [12]. That is real human data, but for a different molecule, a different route and a different condition from the one the committee voted on.

For BPC-157, a 2026 review counted fewer than 30 human participants across three uncontrolled pilot studies, with no completed phase 2 trial [13]. Supporters often point to a Croatian programme in inflammatory bowel disease under the code PL 14736. A 2006 paper by the peptide’s original research group reports that it was safe in those trials [14]; full results from the controlled trials have not appeared in a peer-reviewed journal.

What happens next

The FDA now decides whether to follow the committee. If it does, the route is a proposed rule, a public comment period and a final rule. One law firm following the process says completion could come in 2027 or stretch over several years, and that the FDA may choose to relax enforcement while it runs [4]. Until the FDA says so, the committee’s vote gives pharmacies no protection [9].

What is still open

• Whether the FDA will accept the committee’s recommendations for all six peptides, some, or none.
• The exact epitalon and Semax tallies, until the FDA publishes official minutes.
• When a proposed rule will appear. We found none published as of 10 September 2026.
• What the February 2027 meeting will decide on GHK-Cu and the other four peptides.
• Whether any of these peptides will ever get the controlled human trials the FDA’s reviewers said were missing.

What this means

Our position is that the July vote is a real shift in the regulatory weather and a smaller one than the reaction to it suggests. Six peptides came out of the meeting with a committee recommendation behind them, which is more than they had going in, and the same meeting drew a line at emideltide. That is a committee doing its job, not a verdict on the science.

The useful thing for a reader to hold on to is the distance between a recommendation and the evidence that would normally support one. The FDA’s reviewers opposed all seven nominations on the strength of missing safety and quality data, and a committee can weigh patient demand and clinical experience where it chooses. We would rather see the evidence built than the rules loosened ahead of it, and we think the burden sits with the people making the case for each peptide.

That reading cuts against the loudest voices on both sides. It is a mistake to treat the vote as legalisation: nothing changes for a US pharmacy until a rule is final, and nothing changes at all in the UK. It is just as much a mistake to wave it away. The FDA brought every nomination to the committee after the sponsors had walked away from them, which says something about where the agency’s process is heading.

Where we land: this is the opening of a process with a genuine chance of putting these peptides on the 503A list, and each one should be judged on the human data as it stands rather than on the strength of the vote. The February 2027 meeting on GHK-Cu and the other four peptides will show whether the pattern holds.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.